Preview

Современная ревматология

Расширенный поиск

Фармакотерапия ревматоидного артрита в XXI веке: фокус на ритуксимаб

https://doi.org/10.14412/1996-7012-2009-576

Полный текст:

Аннотация

Ревматоидный артрит (РА) относится к числу наиболее распространенных и тяжелых хронических воспалительных заболеваний. Представлен обзор современных исследований, посвященных оценке эффективности препарата ритуксимаб (Мабтера®) - химерных моноклональных антител к CD20 молекуле В-клеток - у больных РА. Показано, что ритуксимаб является чрезвычайно эффективным и относительно безопасным препаратом для лечения РА и может рассматриваться как прообраз нового направления в лечении аутоиммунных заболеваний, в основе которого лежит модуляция В-клеточного звена иммунитета

Литература

1. <div><p>Насонов Е.Л. Каратеев Д.Е. Ревматоидный артрит. Под ред. Е.Л. Насонова, В.А. Насоновой. М.: ГЭОТАР-Медиа, 2008; с. 852</p><p>Лечение ревматоидного артрита. Клинические рекомендации. Под ред. Е.Л. Насонова. М.: Алмаз, 2006;118 с.</p><p>Bakker M.F., Jacobs J.W.G., Verstappen S.M.M. et al. Tight control in the treatment of rheumatoid arthritis: efficacy and feasibility. Ann Rheum Dis 2007;66:56-60.</p><p>Saag K.G., Teng G.G., Patkar N.M. et al. American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 2008;59:762-84.</p><p>Насонов Е.Л. Фармакотерапия ревматоидного артрита - взгляд в 21 век. Клин мед. 2005;6:8-12.</p><p>Насонов Е.Л. Фармакотерапия ревматоидного артрита в эру генно-инженерных биологических препаратов. Тер. арх 2007;5:5-8.</p><p>Smolen J.S., Aletaha D., Koeller M. et al. New therapies for treatment of rheumatoid arthritis. Lancet 2007;370:1861-71.</p><p>Choy E.H., Panayi C.S. Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001;344:907-16.</p><p>Насонов Е.Л. Применение инфликсимаба (моноклональные антитела к фактору некроза опухоли) в ревматологии: новые данные. РМЖ 2004;20:1123-7.</p><p>Tracey D., Klareskog L., Sasso E.H. et al. Tumor necrosis factor antagonist mechanisms of action: a comprehensive review. Pharmacol Therapeut 2008;117:244-79.</p><p>Smolen J.S., Weinblatt M. When patients with rheumatoid arthritis fail tumor necrosis factor inhibitorsL what is the next step? Ann Rheum Dis 2008;67:1497-8.</p><p>Deng T., Deighton C. Complications of anti-TNF therapies. Future Rheumatol 2007;2, on-line.</p><p>Martin F., Chan A.C. B cell immunobiology in disease: evolving concepts from the clinics. Ann Rev Immunol 2006;24:467-96.</p><p>Youinou P., Jamin C., Saraux A. B-cell: a logical target for treatment of rheumatoid arthritis. Clin Exp Rheumatol 2007;25:318-28.</p><p>Kuhn K.A., Kulik L., Tomooka B. et al. Antibodies against citrullinated proteins anhance tissue injury in experimental autoimmune arthritis. J Clin Invest 2006;116:961-79.</p><p>Reff M.E., Carner K., Chambers K.S. et al. Depletion of B cells in vivo by a chimeric mouse human antibody to CD20. Blood 1994;83:435-45.</p><p>Насонов Е.Л. Перспективы применения моноклональных антител к В-лимфоцитам (ритуксимаб) при ревматоидном артрите. Клин фармакол терапия 2006;1-5:55-8.</p><p>Насонов Е.Л. Применение ритуксимаба при ревматоидном артрите с позиций медицины, основной на доказательствах. Тер арх 2007;12:76-82.</p><p>Smolen J.S., Betteridge N., Breedveld F.C. et al. Consensus statement on the use of rituximab in patients with rheumatoid arthritis. Ann Rheum Dis 26 Oct 2006.</p><p>Rituximab for the treatment of rheumatoid arthritis. Nice technology appraisal guidance 126, 2007.</p><p>Furst D.E., Keystone E.C., Kirkham B. et al. Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2008. Ann Rheum Dis 2008;67:2-25.</p><p>Edwards C.W., Szczepanski L., Szechinski J. et al. Efficacy of B-cell-Targeted therapy with rituximab in patients with rheumatoid arthritis. New Engl J Med 2005;350:2572-81.</p><p>Emery P., Fleishmann R., Filipowicz-Sosnowska A. et al. for the DANCER Study group. The Efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment. Results of a phase IIb randomized, double-blind, placebo-controlled dose-range trial. Arthritis Rheum 2006;54:1390-400.</p><p>Cohen S.B., Emery P., Greenwald M.W. et al. Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 2006;54:2793-806.</p><p>Emery P., Rigby W.F., Combe B. et al. Efficacy and Safety of Rituximab (RTX) as first-line biologic therapy in patients with active rheumatoid arthritis: results of a phase III randomized controlled study (SERENЕ). Arthritis Rheum 2008; ACR 2008, San Francisco, abst 364.</p><p>Rubbert-Roth A., Tak P.P., Bombardieri S. et al. Efficacy and Safety of various dosing regimens of rituximab in patients with active RA: results of a face III randomized study (MIRROR). ACR 2008, San Francisco, abst 363.</p><p>Tak P.P., Rigby W.F.C., Rubbert-Roth A. et al. Rituximab in vombination with methotrexate (MTX) significantly inhibits joint damage and improves clinical outcome in patients with early avtive RA who are naïve to MTX: a randomizrd active comparator placebo-controlled trial (IMAGE). Arthritis Rheum 2009; 60 (Suppl.):S239 (636).</p><p>Keystone E., Fleishmann R., Emery P. et al. Safety and efficacy of additional course of rituximab in patients with active rheumatoid arthritis. An open-label extension analysis. Arthritis Rheum 2007;56:3896-908.</p><p>Keystone E.C., Emery P., Peterfy C.G. et al. Rituximab inhibits structural joint damage in rheumatoid arthritis patients with an inadequate response to tumor necrosis factor inhibitor therapies. Ann Rheum Dis 2008, 3 April, on-line.</p><p>Keystone E.C., Fleishmann R.M., Emery P. et al. Efficacy and safety of repeat treatment courses of Rituximab in RA patients with inadequate response to tumor necrosis factor inhibitors: long-term experience from REFLEX study. ACR 2008; San Francisco, 367 (abst.)</p><p>Cohen S., Keystone E., Genovese M. et al. Continued inhibition of structural damage in rheumatoid arthritis patients treated with Rituximab at 2 years: REFLEX study. ACR 2008; San Francisco; 368 (Abst.).</p><p>Mease P.J., Cohen S., Gaylis N.B. et al. Efficacy, Safety, and dose frequency of retreatment with Rituximab in RA: results from a randomizen controlled trial (SUNRISE). ACR 2008, San Francisco; 1212 (abst.).</p><p>Teng Y., Tekstra J., Breedveld F.C. et al. Rituximab fixed re-treatment versus on-demand re-treatment in refractory rheumatoid arthritis. Ann Rheum Dis 2008; 67 (Suppl. II):339 (FRI0167).</p><p>Edwards J.C.W., Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes. Rheumatology (Oxford) 2001;40:205-11.</p><p>Leandro M.J., Edwards J.C.W., Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002;61:883-8.</p><p>Kneitz C., Wilhelm M., Tony H.P. Improvement of refractory rheumatoid arthritis after depletion of B cells. Scand J Rheumatol 2004;33:82-6.</p><p>Popa C., Leandro M.J., Cambridge G. et al. Repeated B lymphocyte depletion with rit-uximab in rheumatoid arthritis over 7 yrs. Rheumatology 2006; December 19.</p><p>Assous N., Gossec L., Dieude P. et al. Rituximab therapy in rheumatoid arthritis in daily practice. J Rheumatol 2008;35:31-4.</p><p>Vital E.M., Dass S., Rawstron A.C. et al. Combination Rituximab and leflunomide produces lasting responses in rheumatoid arthritis. Ann Rheum Dis 2008; 67 (Suppl. II); 90(OP-0134).</p><p>McGonagle D., Tan A.L., Madden J. et al. Rituximab use in everyday clinical practice as a first-line biologic therapy for the treatment of DMARD-resistent rheumatoid arthritis. Rheumatology 2008;47:865-7.</p><p>Lutt J.R., Deodhar A. Rheumatoid arthritis. Strategies in the management of patients showing an adequate response to TNF antagonist. Drugs 2008;66:591-606.</p><p>Rubbert-Roth A., Finckh A. Treatment options in patients with rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Research Ther 2009; 11 (Suppl. 1):S1.</p><p>St Clair E.W., van der Heijde D.M.F.M., Smolen J. et al. Combination of infliximab and methotrexate therapy for early rheumatoid arthritis. A randomized, controlled trial. Arthritis Rheum 2004;50:3432-43.</p><p>Breedveld F.C., Weisman M.H., Kavanaugh A.F. et al. The PREMIER Study. A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate trearment. Arthritis Rheum 2006;54:26-37.</p><p>Westhovens R., Robles M., Ximenes A.D. et al. Clinical efficacy and safety of abatacept in methotrexate-naive patients with early rheumatoid arthritis. And poor prognostic factors. Ann Rheum Dis 2009l 5 Jan, online</p><p>Emery P., Breedveld F.C., Hall S. et al. Comparison of methotrexate monotherapy with a combination of methotrexate and etanercept in active early, moderate to severe rheumatoid arthritis (COMET): a randomized, double-blind, parallel treatment trial. Lancet 2008; July 16, on line.</p><p>Fleischmann R.M. Safety of biologic therapy in rheumatoid arthritis and other autoimmune diseases; focus on Rituximab. Semin Arthritis Rheum 2008, on line.</p><p>Pham T., Fautrel B., Gottenberg J-E. et al. Rituximab (MabThera) therapy and safethy management. Joint Bone Spain 2008;75:(Suppl. 1):S1-S100.</p><p>Salliot C., Dougados M., Gossec L. Risk of serious infections during rituximab, abatacept and anakinra for rheumatoid arthritis: meta analysis of randomized placebo-controlled trials. Ann Rheum Dis 2008; Jan 18, on line.</p><p>van Vollenhoven R.F., Emery P., Bingham C.O. et al. Long-term safety of rituximab: 6-year follow-up of the RA clinical trials and re-treatment population. ACR 2008; San Francisco; 361 (abst.).</p><p>Genovese M., Breedveld F., Emery P. et al. Safety of other biologic therapies following rituximab treatment in RA patients. Ann Rheum Dis 209; 20 Iune, on-line).</p><p>Blank N., Max R., Briem S. et al. Combination therapy with Rituximab and etanercept for patients with rheumatoid arthritis. Ann Rheum Dis 2008;67(Suppl. II):188.</p><p>Насонов Е.Л., Лукина Г.В., Сигидин Я.А. и др. Применение моноклональных антител к В-лимфоцитам (ритуксимаб) при ревматоидном артрите в России (Предварительные результаты Российского регистра). Тер арх 2008;8:57-63.</p><p>van Vollenhoven R.F., Chatzidionysiou K., Nasonov E. et al. Six-Month results from the collaborative European Registries for Rituximab in Rheumatoid Arthritis (CER-RERA). Efficacy of Rituximab Is Highest in RF-Positive Patients and in those who failed at most one prior Anti-TNF. Arthritis Rheum 2009; 60 (Suppl.):S239 (1671).</p></div><br />


Для цитирования:


Насонов Е.Л. Фармакотерапия ревматоидного артрита в XXI веке: фокус на ритуксимаб. Современная ревматология. 2009;3(4):67-75. https://doi.org/10.14412/1996-7012-2009-576

For citation:


Nasonov E.L. PHARMACOTHERAPY FOR RHEUMATOID ARTHRITIS IN THE 21st CENTURY: FOCUS ON RITUXIMAB. Modern Rheumatology Journal. 2009;3(4):67-75. (In Russ.) https://doi.org/10.14412/1996-7012-2009-576

Просмотров: 790


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)